IL299051A - New peptides and their combinations for immunotherapy against ovarian cancer and other cancers - Google Patents

New peptides and their combinations for immunotherapy against ovarian cancer and other cancers

Info

Publication number
IL299051A
IL299051A IL299051A IL29905122A IL299051A IL 299051 A IL299051 A IL 299051A IL 299051 A IL299051 A IL 299051A IL 29905122 A IL29905122 A IL 29905122A IL 299051 A IL299051 A IL 299051A
Authority
IL
Israel
Prior art keywords
seq
cancer
peptide
cell
tumor
Prior art date
Application number
IL299051A
Other languages
English (en)
Hebrew (he)
Inventor
Schuster Heiko
Peper Janet
Kevin R?HLE
Wagner Philipp
Rammensee Hans-Georg
Original Assignee
Immatics Biotechnologies Gmbh
Schuster Heiko
Peper Janet
Kevin R?HLE
Wagner Philipp
Hans Georg Rammensee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh, Schuster Heiko, Peper Janet, Kevin R?HLE, Wagner Philipp, Hans Georg Rammensee filed Critical Immatics Biotechnologies Gmbh
Priority claimed from PCT/EP2018/051952 external-priority patent/WO2018138257A1/en
Publication of IL299051A publication Critical patent/IL299051A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001163—Phosphatases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
IL299051A 2017-01-27 2018-01-26 New peptides and their combinations for immunotherapy against ovarian cancer and other cancers IL299051A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762451255P 2017-01-27 2017-01-27
DE102017101671 2017-01-27
PCT/EP2018/051952 WO2018138257A1 (en) 2017-01-27 2018-01-26 Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

Publications (1)

Publication Number Publication Date
IL299051A true IL299051A (en) 2023-02-01

Family

ID=61148200

Family Applications (2)

Application Number Title Priority Date Filing Date
IL299051A IL299051A (en) 2017-01-27 2018-01-26 New peptides and their combinations for immunotherapy against ovarian cancer and other cancers
IL268278A IL268278B2 (en) 2017-01-27 2019-07-25 New peptides and their combinations for immunotherapy against ovarian cancer and other cancers

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL268278A IL268278B2 (en) 2017-01-27 2019-07-25 New peptides and their combinations for immunotherapy against ovarian cancer and other cancers

Country Status (23)

Country Link
US (10) US11248035B1 (enExample)
EP (2) EP4035675A3 (enExample)
JP (2) JP7337695B2 (enExample)
KR (2) KR20240134224A (enExample)
CN (1) CN110198734A (enExample)
AU (6) AU2018212584B2 (enExample)
BR (1) BR112019015237A2 (enExample)
CA (1) CA3048108A1 (enExample)
CL (8) CL2019002093A1 (enExample)
CO (1) CO2019008008A2 (enExample)
CR (4) CR20210128A (enExample)
ES (1) ES2946584T3 (enExample)
HR (1) HRP20230512T8 (enExample)
IL (2) IL299051A (enExample)
LT (1) LT3573647T (enExample)
MX (1) MX2019008843A (enExample)
NZ (1) NZ754139A (enExample)
PE (1) PE20191248A1 (enExample)
PH (1) PH12019501377A1 (enExample)
RS (1) RS64217B1 (enExample)
SG (2) SG11201906198PA (enExample)
SI (1) SI3573647T1 (enExample)
TW (1) TW202325724A (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201991444A1 (ru) * 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
AU2018212584B2 (en) 2017-01-27 2020-12-10 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
DE102019114735A1 (de) * 2019-06-02 2020-12-03 PMCR GmbH HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen
CA3150963C (en) 2019-08-28 2023-01-03 Dairycs Automatic Milking Ltd A dairy farm with a single or multiple frontal elevated roads
CA3160506A1 (en) * 2019-11-11 2021-05-20 Ibi-Ag Innovative Bio Insecticides Ltd. Insect control nanobodies and uses thereof
CN110838372B (zh) * 2019-11-18 2022-07-12 武汉大学 一种个性化癌症用药数据库系统及建立方法
CN111363744B (zh) * 2020-02-26 2021-08-24 暨南大学 小檗碱介导的uhrf1基因抑制及其在制备治疗多发性骨髓瘤药物中的用途
EP4165059A1 (en) * 2020-06-13 2023-04-19 Complete Omics Inc. Method and system for neoantigen analysis
CN111735949B (zh) * 2020-07-17 2023-07-21 北京信诺卫康科技有限公司 Wnt7a和CA125联合用作早期卵巢癌生物标志物以及试剂盒
EP4326858A4 (en) * 2021-04-23 2025-03-12 VLP Therapeutics, Inc. GALECTIN-TARGETED IMMUNOTHERAPY
CN114107502A (zh) * 2021-11-29 2022-03-01 四川大学华西医院 一种上尿路上皮癌诊断标志物及其应用
JP2023133869A (ja) * 2022-03-14 2023-09-27 公立大学法人福島県立医科大学 卵巣がん患者の予後予測用バイオマーカー
CN115948557B (zh) * 2023-01-04 2025-09-02 陕西师范大学 一种nlrp2作为靶点在卵巢癌疾病诊断和/或治疗中的应用
CN116350787B (zh) * 2023-03-15 2025-04-01 复旦大学附属金山医院(上海市金山区眼病防治所、上海市金山区核化伤害应急救治中心) Rbm15的抑制剂在卵巢癌紫杉醇化疗耐药中的应用
CN117210561A (zh) * 2023-05-09 2023-12-12 山东第一医科大学第一附属医院(山东省千佛山医院) Rnf106在食管鳞癌检测、治疗和预后靶点及应用
CN116590263A (zh) * 2023-07-02 2023-08-15 广州庆毅生物医药科技有限公司 一种重组蛋白、单克隆抗体及其检测试剂盒和应用
CN117233393B (zh) * 2023-11-15 2024-02-09 四川大学华西医院 双重免疫组化染色试剂盒及其在鉴别良恶性胆管上皮肿瘤中的应用
CN118166098B (zh) * 2024-02-05 2024-09-10 北京大学深圳医院 检测magea4-as1的试剂在制备诊断口腔鳞状细胞癌的试剂盒中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998009638A1 (en) * 1996-09-06 1998-03-12 The Brigham And Women's Hospital, Inc. INHIBITION OF MAST CELL ACTIVATION BY gp49-BASED MECHANISMS AND REAGENTS
US6514935B1 (en) * 1997-03-14 2003-02-04 President And Fellows Of Harvard Methods of treating hypertension
GB0017512D0 (en) * 2000-07-17 2000-08-30 Smithkline Beecham Biolog Novel compounds
WO2003014151A2 (en) * 2001-08-10 2003-02-20 Genset S.A. Human secreted proteins, their encoding polynucleotides, and uses thereof
AU2002324700A1 (en) * 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
US6906036B2 (en) * 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1545610A4 (en) * 2002-09-06 2006-11-08 Mannkind Corp EPITOPE SEQUENCES
WO2005017102A2 (en) * 2003-05-30 2005-02-24 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
JP4926714B2 (ja) * 2003-11-19 2012-05-09 サーバック エーピーエス Ｂｃｌ−２ファミリ−に属するタンパク質およびそのフラグメント、ならびに癌患者におけるそれらの使用
CA2598889A1 (en) * 2005-02-24 2006-08-31 Cemines, Inc. Compositions and methods for classifying biological samples
DE602005020046D1 (de) 2005-09-05 2010-04-29 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
EP3533461A3 (en) * 2007-03-26 2019-12-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Prame derived peptides and immunogenic compositions comprising these
HUE025636T2 (en) * 2007-07-27 2016-04-28 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
DK2280721T3 (da) * 2008-04-17 2018-01-29 Io Biotech Aps Indoleamin-2, 3-dioxygenasebaseret immunterapi
EP2113253B1 (en) 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
PT2119726E (pt) 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
GB201006360D0 (en) * 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2012048291A2 (en) * 2010-10-08 2012-04-12 Proteapex Therapeutics Llc Compositions and methods for inhibition of mmp:mmp-substrate interactions
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) * 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201512369D0 (en) 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
AU2018212584B2 (en) * 2017-01-27 2020-12-10 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
EA201991444A1 (ru) 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods

Also Published As

Publication number Publication date
US20230365651A1 (en) 2023-11-16
PE20191248A1 (es) 2019-09-18
CL2019002093A1 (es) 2019-11-29
US11919940B2 (en) 2024-03-05
BR112019015237A2 (pt) 2020-04-14
KR20240134224A (ko) 2024-09-06
US11858978B2 (en) 2024-01-02
NZ754139A (en) 2022-07-01
AU2021201350B2 (en) 2024-02-01
PH12019501377A1 (en) 2020-02-10
AU2018212584A1 (en) 2019-06-20
CR20190388A (es) 2019-10-16
US20230312680A1 (en) 2023-10-05
KR20190112271A (ko) 2019-10-04
EP3573647A1 (en) 2019-12-04
AU2021201346A1 (en) 2021-03-18
US11345737B1 (en) 2022-05-31
AU2021201348A1 (en) 2021-03-18
ES2946584T3 (es) 2023-07-21
US20230002473A1 (en) 2023-01-05
CO2019008008A2 (es) 2019-10-21
EP4035675A2 (en) 2022-08-03
HRP20230512T8 (hr) 2023-09-15
EP4035675A3 (en) 2022-11-16
US20210340216A1 (en) 2021-11-04
AU2021201350A1 (en) 2021-03-18
US20240034769A1 (en) 2024-02-01
US20240076349A1 (en) 2024-03-07
RS64217B1 (sr) 2023-06-30
MX2019008843A (es) 2019-12-09
CL2022002923A1 (es) 2023-04-14
US11214608B2 (en) 2022-01-04
JP2023179415A (ja) 2023-12-19
US11248035B1 (en) 2022-02-15
IL268278A (en) 2019-09-26
US12065477B2 (en) 2024-08-20
CL2020000817A1 (es) 2020-10-16
CR20210128A (es) 2021-04-26
SG10202108122YA (en) 2021-09-29
LT3573647T (lt) 2023-06-12
TW202325724A (zh) 2023-07-01
AU2021201350B9 (en) 2024-02-22
AU2021201347A1 (en) 2021-03-18
SG11201906198PA (en) 2019-08-27
CA3048108A1 (en) 2018-08-02
CR20210130A (es) 2021-03-31
SI3573647T1 (sl) 2023-07-31
KR102699622B1 (ko) 2024-08-28
AU2021201349A1 (en) 2021-03-18
EP3573647B1 (en) 2023-04-05
CN110198734A (zh) 2019-09-03
CL2021002460A1 (es) 2022-06-24
AU2018212584B2 (en) 2020-12-10
CL2021002461A1 (es) 2022-06-24
JP7337695B2 (ja) 2023-09-04
CR20210129A (es) 2021-03-26
CL2021002459A1 (es) 2022-06-24
CL2022003407A1 (es) 2023-05-26
CL2022003406A1 (es) 2023-05-26
US20220356227A1 (en) 2022-11-10
HRP20230512T1 (hr) 2023-08-04
US20230002474A1 (en) 2023-01-05
IL268278B2 (en) 2023-05-01
IL268278B1 (en) 2023-01-01
JP2020506690A (ja) 2020-03-05

Similar Documents

Publication Publication Date Title
de Oliveira et al. Long non‐coding RNAs in cancer: another layer of complexity
US11919940B2 (en) Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
Shin et al. Down-regulation of dual-specificity phosphatase 5 in gastric cancer by promoter CpG island hypermethylation and its potential role in carcinogenesis
Huang et al. SNHG8 is identified as a key regulator of epstein-barr virus (EBV)-associated gastric cancer by an integrative analysis of lncRNA and mRNA expression
Huang et al. TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis
US11840562B2 (en) Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
Planells-Palop et al. Human germ/stem cell-specific gene TEX19 influences cancer cell proliferation and cancer prognosis
Sun et al. RETRACTED ARTICLE: Long Non-Coding RNA LEF1-AS1 Promotes Migration, Invasion and Metastasis of Colon Cancer Cells Through miR-30-5p/SOX9 Axis
Kulaeva et al. mRNA-lncRNA gene expression signature in HPV-associated neoplasia and cervical cancer
Xu et al. Genetic features of TP53 mutation and its downstream FOXA1 in prostate cancer
Hasan An overview of promising biomarkers in cancer screening and detection
Xie et al. nMET, a new target in recurrent Cancer
Cho et al. Human Puf-A, a novel component of 90S pre-ribosome, links ribosome biogenesis to cancer progression
CN118317783A (zh) 肽疫苗
Hasan Exploring the role of Indian Hedgehog in regulating immunogenicity in colorectal cancer
Finn Novel Mechanisms of Resistance to Enzalutamide in Prostate Cancer
Chen et al. Mechanism of competitive binding of miR-106b-5p by circRNA-ITCH to target and regulate SETD2 to inhibit prostate cancer progression
Brune et al. Appendix A: Loss of IRF5 increases ribosome biogenesis leading to alterations in mammary gland architecture and metastasis
Ma et al. H3K27ac-induced lncRNA PAXIP1-AS1 exhibits oncogenic property in ovarian cancer by targeting miR-6744-5p/PCBP2 axis
Chiadini Study of the interactions between CD99, immunologic microenvironment and microRNAs and their prognostic significance in human osteosarcoma
Gonçalves Deciphering Key Roles of WNT6 in Glioblastoma: Mechanistic, Functional, and Clinical Insights
Kolla et al. in Human Cancers: 10 Years Later CHD5 Role of
Rogers Cancer gene discovery and immunosurveillance studies using Sleeping Beauty mouse models